Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Daily News

Review Spotlights SCAD Diagnosis and Treatment

L.A. McKeown

December 15, 2020

News Features

Too Easy to Misconstrue: Is It Time to Ditch Periprocedural MI?

Michael O'Riordan

December 02, 2020

News Daily News

Colchicine in the Crosshairs for Its High US Cost

Caitlin E. Cox

December 01, 2020

News Conference News AHA 2020

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Michael O'Riordan

November 12, 2020

News Conference News ESC 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

L.A. McKeown

September 03, 2020

News Opinion CV Team Dispatch

September 2020 News Roundup

L.A. McKeown

September 01, 2020

News Daily News

Early Revascularization in NSTEMI Linked to Lower Mortality: AHRQ Analysis

Michael O'Riordan

August 20, 2020

News Features

COVID-19’s Enduring Impact on the Heart? Some Clues and Predictions

Shelley Wood

July 20, 2020

News Daily News

Thrombus Burden Greater in STEMI Patients With COVID-19

Michael O'Riordan

July 20, 2020

News Daily News

Less MI, CV Death With Noninvasive Testing for Chest Pain: Observational Data

Michael O'Riordan

July 14, 2020

News Daily News

PAD Patients Undertreated With Statins Despite Elevated CV Risk

L.A. McKeown

July 13, 2020

News Conference News EuroPCR 2020

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

Michael O'Riordan

June 26, 2020

News Daily News

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

Caitlin E. Cox

June 25, 2020

News Conference News ACC 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

Shelley Wood

March 30, 2020

News Daily News

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Shelley Wood

March 10, 2020

News Daily News

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

Shelley Wood

March 04, 2020

News Daily News

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

Caitlin E. Cox

February 07, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

Advertisement

Review Spotlights SCAD Diagnosis and Treatment

Too Easy to Misconstrue: Is It Time to Ditch Periprocedural MI?

Colchicine in the Crosshairs for Its High US Cost

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

September 2020 News Roundup

Early Revascularization in NSTEMI Linked to Lower Mortality: AHRQ Analysis

COVID-19’s Enduring Impact on the Heart? Some Clues and Predictions

Thrombus Burden Greater in STEMI Patients With COVID-19

Less MI, CV Death With Noninvasive Testing for Chest Pain: Observational Data

PAD Patients Undertreated With Statins Despite Elevated CV Risk

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content